The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
As opposed to tick tock
https://www.tiktok.com/@optibiotix
i'm no expert re tiktok/instagram/facebook etc
but the numbers following etc the above are pathetic after all this time
and i cannot access the optibiotix website on firefox since my return from holiday
The page you are trying to view cannot be shown because the authenticity of the received data could not be verified.
Please contact the web site owners to inform them of this problem.
nothing on boots either
jees some things never change with opti
as i have previously noted - i'm giving him to end of this year - at the latest - tick tock
mind not that he will give a ........... and nor should he in response to a BB and his latest placing to keep the lights on
nevermind the gloss put on it within the rns
mol
I Have a Dream, a song to sing
To help me cope, with anything
If you see the wonder, of a fairy tale
You can take the future, even if you fail
I believe in angels
Something good in everything I see
I believe in angels
When I know the time is right for me
I'll cross the stream, I Have a Dream
I Have a Dream, a fantasy
To help me through, reality
And my destination, makes it worth the while
Pushin' through the darkness, still another mile
Didn't I would be tempted to post the above and obvious to the thread
But couldn’t help myself lol
mol
Recent Developments
Last Updated: 22/03/2024
SBTX accompanied their half year results on 22 March with an interesting Investor Meet presentation, which can be found on the site, and featuring alongsideCEO Stuart Ashman the CFO, the Sederma (Croda) trials director and the CEO of the recent Dematonics acquisition. Revenues remain low (£107,000 + 38%), but they have signed up a new partner to market their psoriasis product via Amazon. Key points from the RNS and presentation included:
Final clinical trial stage to complete May/June of 5 year work with Sederma- now not binary, but a question of whether they can launch with clinical claims and correspondingly higher price point or not.
Marketing deal for Axisbiotix with World Products via Amazon, who they have got to know through Dermatonics acquisition
Dermatonics has high but as yet unquantified hopes for sales in Asia via the Umesh Modi group.
They are looking at cutting raw material costs.
Will launch an acne product this year. The data for the 220 person study backing this up was released in an RNS in February.
Unwinding CLN arrangement but say they now have potential of alternative funding lines for other acquisitions.
CEO and CFO have taken 20% pay cut after criticism of their pay.
Operating loss was £1.39m vs £1.35m, cash at end December £2.84m vs £1.31m at end June, after a £3.3m gross placing in November.
SBTX announced a new six-month research project (“Epidem”) at Manchester University on 18 March, which they are co-funding, to look at the use of non-pathogenic bacteria in wound healing. It will be run by two professors. At the same time they announced that their (Manchester-based) CSO, Professor Cath O’Neill, is stepping back from her role to “return to academia” but will remain as a Scientific adviser.
mol
By another
Investment Case
SkinBioTherapeutics is potentially well positioned to be a leader in the skin health probiotic market. The company has two active developments arms: SkinBiotix is a partnership with Croda in developing new anti-ageing products (the collaboration contract was extended for 12 months in October). AxisBiotix is a food supplement to treat psoriasis sufferers which was introduced to the market through a pilot launch both in the UK and the USA in November 2022. The company is targeting significant markets with its lead opportunities but so far has not yet made material progress, so positive consumer reviews are encouraging. As well as psoriasis and cosmetics applications, SBTX has in the past referred to other potential applications for their formulations, including wound care (Medbiotix), oral health and acne – where progress on the patient study has now been reported.
The Direct-to-Consumer launch of AxisBiotix in late 2021 did not initially generate the hoped-for sales in the UK and the company acknowledged that it needed to change its marketing strategy and is looking for a global distributor. Launches in Europe are being done directly by the company. The timing of progress with Croda is very reliant on Croda’s internal processes. SBTX remains a very small company tackling very large categories and success would be transformative but is dependent on take-up by larger companies.
Brokers Cavendish has June 2024 forecasts of £1.1m revenues (so a big ramp up from H1, but starting to show the benefit of Dermatonics), £2.4m loss at EBITDA level and net debt of £600,000. For the next year the key will be for when and to what extent royalties start flowing from the Croda relationship. Cavendish revised its numbers after the Dermatonics announcement to a target of 48p, slightly down taking into account the new convertible note. As things stand this seems very distant and the company will need to provide clarity on future funding, as well as meeting the now heightened expectations of a launch with Croda.
That would be the 5m loan note announced on 25 Jan 2024 only for this on 28 Feb 24 - what's that under 5 weeks
To date, the Company has drawn a total of £1,600,000 under the Facility. The Board of SkinBioTherapeutics has today provided formal notice to CLG Capital LLC (CLG) (and by proxy Macquarie) that it will not utilise the reminder of the £5m Facility. The Board is in negotiations with the noteholders to discuss timing and rate of conversion and subsequent selling of stock.
Stuart Ashman, CEO of SkinBioTherapeutics said: "We met the CLG team today and have come to an amicable agreement around the Facility and next steps. We believe this is the right decision for the Company. In the meantime, we are very busy integrating the recently acquired Dermatonics, the accelerated Modi/Dermatonics product launch in the Asia, Middle East and Africa regions, and completing the participant study for the acne programme which has generated very positive interim results. We anticipate further updates in the coming weeks in the lead up to the HY results in March."
whilst as Bazza notes on 22nd March the cln was the best option.........
jees if any further evidence was ever needed
the cln note is not the only thing that overhangs this company
mol
On sale from 23 Feb 2024
https://www.amazon.co.uk/MuscleTech-NitroTech-Weightloss-Servings-Chocolate/dp/B0CW9Y256T/ref=sr_1_8?dib=eyJ2IjoiMSJ9.j2lnQLFdow5hZMjAS0VapCW7FprAvMaME9nY1JiRN4HvrT781gvZsEgS7M6k8dmtsO-TxY7Y589UwAM7D80WZnQZqdpvJTZcQOKnrE58YFmtipjeEXfKCyit0qWOM78_mnAZ504hFCudnRdlMMWKxnp5rQEXmlfh73xirR3Xcyvpv6CfGEporeBmt6gclph5zwx4JSvUj43aTVM85t3H1IVRssG3G6_7ze1OAu8219oEd_S3dfyFnOnFWFpoXl-hlnN2s8LQYrOXgOuV8a4znoOOP-rJq-gNS3CPn2RMe0U.l7IBC4HFcLPQmKexMIM_OJsAmwZ0bGiMPcsNA9ctAT0&dib_tag=se&keywords=nitrotech+ripped+protein&qid=1711647399&sr=8-8
and
https://www.amazon.co.uk/MuscleTech-NitroTech-Protein-Weightloss-Servings/dp/B0CW9Y3LB4/ref=sr_1_10?dib=eyJ2IjoiMSJ9.j2lnQLFdow5hZMjAS0VapCW7FprAvMaME9nY1JiRN4HvrT781gvZsEgS7M6k8dmtsO-TxY7Y589UwAM7D80WZnQZqdpvJTZcQOKnrE58YFmtipjeEXfKCyit0qWOM78_mnAZ504hFCudnRdlMMWKxnp5rQEXmlfh73xirR3Xcyvpv6CfGEporeBmt6gclph5zwx4JSvUj43aTVM85t3H1IVRssG3G6_7ze1OAu8219oEd_S3dfyFnOnFWFpoXl-htmH9UvsX5v_yggSDq5HVnlrEqoHkoMLXVZnm3Bf-fGI.QAePYc7xczEiBqffbdXuz7YDIQOSSlw0c8m3CjlDeZg&dib_tag=se&keywords=nitrotech+ripped+protein&qid=1711647780&sr=8-10
there may be other flavours but you get the gist at least on sale in europe
nowt so far re boots online - as far as i can decipher
mol
Https://www.nasdaq.com/press-release/verona-pharma-reports-fourth-quarter-and-full-year-2023-financial-results-and
sound familiar?
mol
True regarding reporting every quarter with a wealth of info not available /required under aim
However VRP went down that route ..........
and I know how that went and it wasn't a success (jees they even rang the opening bell to rapturous applause)
delisted from aim c 2020
however their ADS still on nasdaq under vrna
https://www.nasdaq.com/market-activity/stocks/vrna
mol
They have released their own press release dated 18th Mar but i believe actually released to public today 19th
Gurugram, India – March 18, 2024 – Dr. Morepen, a trusted brand from Morepen
Laboratories (NSE: MOREPEN) known for household staples like Burnol and Lemolate,
announced a partnership with OptiBiotix Health plc (AIM: OPTI) to introduce a transformative
weight management solution to the Indian market.
"At Dr. Morepen, we've consistently empowered individuals to lead healthier lives," said
Varun Suri, CEO – Consumer Care at Morepen. "This collaboration with OptiBiotix’s
SlimeBiome (sic) allows us to take a significant step forward in addressing the alarming rise of
obesity in India.”
https://www.morepen.com/public/uploads/media/Morepen65f982b98b079.pdf
transformative and significant - their words
mol
Not sure that you have converted indian rupees or lakh to sterling correctly aquae
their financial statements look pretty impressive to me
and didn't note slimbiome on link provided
but if you have found your assertion re spending a lot of money promoting - i'll take that all day long
mind i also thought you would be one of the first to study links provided
best wishes
mol
Sold out? jees did they not order enough?
or is this just a prelim page on their website in advance of launch
https://muscletech.co.uk/products/nitro-tech-ripped
mol
Plenty of info available for anyone interested
https://www.morepen.com/investors
https://economictimes.indiatimes.com/morepen-laboratories-ltd/stocksupdate/companyid-11215.cms
and latest results (to Dec 23 and available as from 31 Jan 24 ) albeit not audited and whilst they will have an accounting team behind same - they will also have an abundance of transactions to record above our scant number
no reason why we cannot do the same once myers beds in - i'm not holding my breath though ( and it was once muted re a listing on nasdaq - can't remember who discussed it on here at time lol - I said at time not going to happen and continue to hold said view )
https://www.morepen.com/public/uploads/investor/Morepen65bb97fa1e35f.pdf
mol
4 hours ago
Stick with it...
I am 6 months in, haven't missed a day and most importantly...haven't done anything else. 20 plus years of on and off psoriasis. Covid and family losses collided and from 2020 I'd been in a flare which saw, small patches grow and join until my body was around 80/90% covered. Badly, deep deep flare. I am now down to 50% and that 50% is not deep, nowhere near as cracked,layered and sore. It will all be gone for good by my 12 month AxisBiotix anniversary!!🎉
Date of experience: 12 March 2024
8 hours ago
Impressed!!
Stick with it! I really, really like this product but it does take time to kick in. I am now 3 months in and have just started to see a positive effect. I’ve suffered with psoriasis for about 10 years, predominantly scalp psoriasis and plaques across my stomach and back. I’ve tried lots of treatments under a dermatologist, from steroid creams to immunosuppressants drugs. Whilst effective, I found them quite harsh and not really long term solutions.
Since starting AxisBiotix, the plaques on my body have completely cleared and I am now able to manage my scalp psoriasis with a topical shampoo, rather than a daily steroidal ointment soak.
I am interested to see how the next 6 months go.
mol
Professor McBain at this conference in June
Presentation Outline
The potential role of the microbiome in overall skin health and in skin ageing is being increasingly recognised. Microbiome research is often complicated by considerations of correlation versus causation, and this applies to studies of human ageing as much as anywhere else. However, ageing-related changes in microbiome composition have been reported and ongoing research should focus on potential mechanisms, which may involve direct interaction with the skin and the host immune system, and the production of microbial metabolites. Microbiome-based interventions, such as probiotics, prebiotics, and postbiotics, have emerged as potential therapeutic strategies to modulate the skin microbiome and promote healthy skin ageing. This presentation will explore the current understanding of the skin microbiome's role in ageing and discuss potential microbiome-based interventions for promoting healthy skin ageing.
https://summit-events.com/anti-ageing/speaker-programme
mol
Or not perhaps
https://www.dermatonics.co.uk/collections/shop
heel balm, as anyone here, should know just one of a number of products making up the last reported turnover of £1.86m
which i found underwhelming given the price paid
and i'm also not overly impressed with umesh modi website - nor their turnover - at least what appears to be their reported turnover - as one who has tried over a number of years to gain an insight into privately owned companies in India - not an easy exercise and also, whilst an extemely large potential market, not one that readily avails itself to outside companies.
but after all the back slapping and self promotion amongst a number of posters here
nobody has actually then put a figure on the increased turnover expected in say year ended 31 Jun 2025 - or am i wrong - but even more importantly profit before tax to bottom line from this
20 February 2024 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that its newly acquired company Dermatonics is set to launch Pheet and Dermatonics Once Heel Balm in Asia, Middle East and Africa (AMEA) in partnership with the Umesh Modi Group (the Group) following the signing of a manufacturing and distribution agreement on 30 June 2023.
Pheet and Dermatonics products are used for the treatment of dry foot skin and are sold under the Dermatonics brand in the rest of the world. The Once Heel Balm product will be manufactured by the Umesh Modi Group and sold directly by its sales team of over 1,200 people across six countries including India, Bangladesh Sri Lanka and Nigeria. The total addressable market in these regions for dermatology and diabetes management is in excess of £5bn. This collaboration is currently at an early stage, therefore, the management does not expect any changes to current market expectations at this stage.
mad after all
mol
Https://soundcloud.com/optibiotix-investor/february-29th-2024
Something to listen to over the weekend
mol